According to the current analysis
of Reports and Data, the global Amoxicillin
market was valued at USD 4,408.1 million in 2018 and is expected to
reach USD 4,962.6 million by the year 2026, at a CAGR of 1.5%. The amoxicillin
antibiotics is a generic category of drug. It is also known by the name Amoxil
and is usually administered in the treatment involving bacterial infections.
The compound belongs to the β-lactam drug class of antibiotics. The amoxicillin
medication is used in treating infections such as, pneumonia, ear infections,
bronchitis, sinusitis, infections of the skin, and urinary tract infection
(UTI). Its use for UTI is found to be used most than any other antibiotics.
This antibiotic can also be taken in combinations with other drugs, such as
amoxicillin and clavulanate potassium, it is used for treating bacterial
infections mentioned before. The use of amoxicillin antibiotics for tooth
infection is also popular. The increasing frequencies of bacterial infections
in low-income countries, developing countries and other parts of the world will
be the most significant factor in driving the growth of this market. Also the
increasing research and applications of combination drugs with this medication
will fasten the progress of the market. Furthermore, these medicines are safe
to be taken together with birth control pills. Although, the possible side
effects of amoxicillin are expected to hamper the development of the market to
some extent.
The market is segmented on the
basis of the diseases, the route administration, drug formulation, and
distribution channels involved in distributing the medicine. The medication is
available in tablet, capsule, suspension, syrup, and powder form, through
hospital pharmacies, drug stores, retail stores and online pharmacies. It can
be taken orally and through intravenous route as well. Some specific combinational
medications are also prescribed for pregnant women. It includes, erythromycin
or clarithromycin in combination with amoxicillin if the patient is pregnant
with moderately severe infection; and Co-amoxiclav with clarithromycin, or
erythromycin if the patient is pregnant with high-severity infection.
On the basis of geography, the
North America segment is observed to be the fastest growing market, owing it to
the growing number of clinical trials, research and development scenarios in
the region. Europe is expected to perform good with Asia Pacific expected to
growth with the highest CAGR across the world. Europe segment growth is
anticipated to get impeded to some extends due to the announcement by
government about its decision to reduce antibiotic prescriptions by around 15%
this year, as part of a new plan to control antimicrobial resistance by 2040.
Furthermore, increased government
initiatives for encouraging the use of this medicine, availability of research
funds from private as well as public bodies, improvement in the reimbursement
scenario, and rising awareness about multiple benefits of amoxicillin
prescription are among the key factors propelling the growth of the market.
Other medication alternatives of antibiotic amoxicillin are anticipated to impede
the market growth. However according to a recent update from Journal of the
American College of Cardiology it was found that Cipro or Ciprofloxacin, owns
huge risk of escalating a heart-valve problem than another broad-spectrum
antibiotic specifically amoxicillin.
To identify the key trends in
the industry, click on the link below:
No comments:
Post a Comment